Autopsy report · NCT01433016

Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI

“Due to budgetary issues, the company has decided to focus on other applications at this stage.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 1 year 6 months before it stopped.
• 20 participants enrolled.
• Results were posted on the registry 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Meridian Bioscience, Inc.

Sponsor type

Industry

Conditions

Chronic Liver Disease; Hepatocellular Carcinoma (HCC)

Interventions

13C Sodium Octanoate

Participants

20

Sites

1

Countries

Canada

Trials that died the same way

• Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer
  “company focus on other projects” (55% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.